Boehringer Ingelheim significantly expands its supply center for China

Boehringer IngelheimBoehringer Ingelheim intends to invest 70 million Euro to expand its manufacturing plant in the Zhangjiang High-Tech Park in Shanghai into a strategically important supply center for China. The goal of this project is to bring more health to more patients and to continuously improve Boehringer Ingelheim's product competitiveness and enlarge its market share.

With the expansion until end of 2013, the number of employees will rise significantly from 240 today to 400, the production capacity will be doubled.

"We want to expand our Zhangjiang plant, primarily to meet the demand for more health in China. It also shows our continuous commitment to China and specifically Shanghai", said Professor Dr Wolfram Carius, responsible for the Corporate Board Division Operations and Human Resources. "Our vision is to transform our Shanghai plant into a launch site in Boehringer Ingelheim's global Operations network."

The project intends to build a modular and lean manufacturing facility on the current production site. It will be able to produce marketed products and new pipeline products. The objective to have world-class production through a lean manufacturing approach will be supported by the optimisation of material flow and by our highly qualified employees.

In the first phase, which will be completed by the end of December 2013, a packaging center for ampoules and solids and a new automatic warehouse will be constructed. Furthermore, a new laboratory building for development activities will be set up on the site. In the second phase, to be concluded until the end of 2014, the existing solids manufacturing facility will be revamped and upgraded with new technologies.

The pharmaceutical industry is currently in the focus of Shanghai's economic strategy. Boehringer Ingelheim China’s strategy is in tune with the economic structure transformation advocated by the government and will lead the company into a new phase of development. "We are committed to meeting the growing demand of China's pharmaceutical market and to bringing more health to patients and their families", said David Preston, Chief Executive Officer of Boehringer Ingelheim China.

Since it entered the Chinese market in 1994, Boehringer Ingelheim has expanded its product range to cover respiratory, cardiovascular, central nervous system and other important therapeutic areas. In the forthcoming years, the company will continue to expand, including the therapeutic areas diabetes, oncology and stroke prevention.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavours.

In 2010, Boehringer Ingelheim posted net sales of about 12.6 billion euro while spending almost 24% of net sales in its largest business segment Prescription Medicines on research and development.

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...